Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

RNA-seq of pancreatic mouse tumor cell lines


ABSTRACT: KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and resistant to targeted therapies, immune checkpoint blockade and engineered T cells. In this study, we performed a systematic high throughput combinatorial drug screen and identified a synergistic interaction between the MEK inhibitor trametinib and the multi-kinase inhibitor nintedanib. Using bulk and single-cell RNA sequencing and immunophenotyping, we show that the combination therapy reprograms the immunosuppressive microenvironment and primes cytotoxic and memory T cells to infiltrate the tumors, thereby sensitizing mesenchymal PDAC to PD-L1 inhibition.

INSTRUMENT(S): NextSeq 500

ORGANISM(S): Mus musculus

SUBMITTER: Chiara Falcomatà 

PROVIDER: E-MTAB-11187 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2021-07-05 | E-MTAB-10515 | biostudies-arrayexpress
2023-03-02 | E-MTAB-9878 | biostudies-arrayexpress
2024-04-06 | E-MTAB-13946 | biostudies-arrayexpress
2022-09-29 | E-MTAB-11036 | biostudies-arrayexpress
2023-03-27 | E-MTAB-12495 | biostudies-arrayexpress
2021-12-26 | E-MTAB-11242 | biostudies-arrayexpress
2023-07-07 | E-MTAB-12746 | biostudies-arrayexpress
2020-08-21 | E-MTAB-9221 | biostudies-arrayexpress
2021-03-24 | E-MTAB-9969 | biostudies-arrayexpress
2019-07-07 | E-MTAB-6921 | biostudies-arrayexpress